Patents Examined by Taofiq A. Solola
  • Synthetic base and associated methods
    Patent number: 11311036
    Abstract: Glycine is an organic compound that can be used in the making of a synthetic base that obviates all the drawbacks of strong bases such as sodium hydroxide. The new compound is made by dissolving glycine in water and adding calcium hydroxide at a molar ration of about 1:1. Next, sodium percarbonate is dissolved in the solution to produce the new compound, which can be referred to as glycine hydroxide.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: April 26, 2022
    Assignee: Green Products & Technologies, L.L.C.
    Inventor: John T. MacDonald
  • Compositions and methods for restoring epidermal integrity and function and treating dermatological diseases
    Patent number: 11312725
    Abstract: Novel isohexide esters and isohexide compositions are prepared and used in improving skin health and condition.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: April 26, 2022
    Assignee: Sytheon Limited
    Inventor: Ratan K Chaudhuri
  • Methods of diagnosing and treating Tourette syndrome
    Patent number: 11298347
    Abstract: Methods and uses for diagnosing and treating Tourette syndrome are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: April 12, 2022
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Hakon Hakonarson, Charlly Kao
  • Purinone derivative hydrochloride
    Patent number: 11292795
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: April 5, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Therapeutic aurones
    Patent number: 11286245
    Abstract: Substituted aurones were found to have antitrypanosomal, antifungal and immunomodulatory activity. The invention provides novel aurone compounds, pharmaceutical compositions, and methods encompassing medical and veterinary applications.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: March 29, 2022
    Assignee: MIDDLE TENNESSEE STATE UNIVERSITY
    Inventors: Jeannie Stubblefield, Zachary E. Taylor, Scott Handy, Anthony Newsome
  • Ceftolozane antibiotic compositions
    Patent number: 11278622
    Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: March 22, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandron Donadelli, Dario Resemini
  • GAS5 binding compounds, formulations, and uses thereof
    Patent number: 11278521
    Abstract: Provided herein are compounds that can bind GAS5 long non-coding RNA, compositions thereof, and uses thereof.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: March 22, 2022
    Assignees: UNIVERSITY OF SOUTH FLORIDA, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS OFFICE OF GENERAL COUNSEL—PSG IV (024)
    Inventors: Niketa A. Patel, Jianfeng Cai
  • NEK inhibitors and methods of use
    Patent number: 11279707
    Abstract: Compounds of the present application or pharmaceutically acceptable salts thereof are provided and methods involving compounds of the present application as effective inhibitors of NEK are also provided.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 22, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Quan Cai, Tinghu Zhang
  • Compositions and methods for the treatment of presbyopia
    Patent number: 11273150
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The methods preferably comprise storing an aceclidine composition in a container having a headspace at a temperature from about 2 to about 8 degrees Celsius. The methods further comprise filling the container under an inert gas overlay and/or enclosing the container an anti-leaching material or disposing the container in a second container containing an anti-leaching material.
    Type: Grant
    Filed: October 13, 2020
    Date of Patent: March 15, 2022
    Assignee: LENZ THERAPEUTICS, INC.
    Inventor: Gerald Horn
  • Diamino pyridine derivatives
    Patent number: 11274080
    Abstract: The present invention describes novel diamino pyridine derivatives exhibiting JAK modulating properties. The present invention also relates to pharmaceutical compositions comprising these novel compounds, methods of using said compounds in the treatment of various diseases and disorders being susceptible to JAK modulation, and processes for preparing the compounds described hereinafter.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: March 15, 2022
    Assignee: Novartis AG
    Inventor: Gebhard Thoma
  • Boronic acid derivatives
    Patent number: 11274109
    Abstract: ?-amino boronic acid derivatives are useful for inhibiting the activity of immunoproteasome (LMP7) and for the treatment and/or prevention of medical conditions affected by immunoproteasome activity such as inflammatory and autoimmune diseases, neurodegenerative diseases, proliferative diseases and cancer.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 15, 2022
    Assignee: Merck Patent GmbH
    Inventors: Markus Klein, Oliver Schadt, Christina Esdar
  • Hybrid materials for biochemical applications
    Patent number: 11262353
    Abstract: Materials and methods for the design of hybrid materials comprising a conducting matrix, organic modifiers/linkers and modifying molecules.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: March 1, 2022
    Assignee: UNM Rainforest Innovations
    Inventors: Nikolai Kalugin, Alexey Serov, Lindsay Candelaria, Peter Kalugin
  • Bradykinin B2 receptor antagonists
    Patent number: 11261173
    Abstract: The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: March 1, 2022
    Assignee: PHARVARIS NETHERLANDS B.V.
    Inventors: Christoph Gibson, Joern Saupe, Horst-Dieter Ambrosi, Lars Ole Haustedt
  • Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection
    Patent number: 11253500
    Abstract: The present invention relates to or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: February 22, 2022
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: David Barros Aguirre, Robert H. Bates, Ruben Gonzalez Del Rio, Alfonso Mendoza Losana, Santiago Ramón García
  • Salt forms of organic compound
    Patent number: 11242321
    Abstract: A salt compound of 4-(2-((4-bromophenyl)thio)acetamido)-1-phenethyl-1H-pyrazole-3-carboxylic acid is disclosed. Also disclosed are methods for making the salt compound and formulations of the salt compound into dosage forms for clinical use.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: February 8, 2022
    Assignee: Kainos Medicine Inc.
    Inventors: Jae Moon Lee, Sungeun Yoo, Sunmi Shin
  • Inhalable imatinib formulations, manufacture, and uses thereof
    Patent number: 11229650
    Abstract: The invention relates to inhalable imatinib formulations, manufacture, and uses thereof.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: January 25, 2022
    Assignee: Aerovate Therapeutics, Inc.
    Inventors: Ben Dake, Ralph Niven, Andrew D. Levin
  • P2X7 modulators
    Patent number: 11225478
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: January 18, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • 4-substituted benzoxaborole compounds and uses thereof
    Patent number: 11214582
    Abstract: Substituted benzoxaboroles whose structure comprises Formula (III), wherein R3 is selected from —CH3, —CII2CII3, —CII2?CII2, —CII2CII2CII3, —CH(CH3)2, —CH2CH2?CH2, and cyclopropyl, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, and —CH(CH3)2; compositions containing such compounds, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: January 4, 2022
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, ANACOR PHARMACEUTICALS, INC.
    Inventors: Carlos Alemparte-Gallardo, Michael Richard Kevin (Dickon) Alley, David Barros-Aguirre, Ilaria Giordano, Vincent Hernandez, Xianfeng Li, Jacob J. Plattner
  • Ready-to-administer fentanyl formulations
    Patent number: 11207309
    Abstract: The stable liquid formulations for parenteral administration include fentanyl or a pharmaceutically acceptable salt thereof. The formulations include a diluent and buffer, either containing sodium, in an aqueous solution that has a pH of about 3 to about 4.5. The parenteral liquid formulations are stable formulations that are supplied as a ready-to-administer product in an infusion container or bag. The stable formulations are terminally sterilized in the infusion container. The stable formulations are suitable for administration to a patient in need of therapy with fentanyl or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: December 28, 2021
    Assignee: Hikma Pharmaceuticals International Limited
    Inventors: Andrew Conrad, Ragheb Al-Shakhshir, Ragheb AbuRmaileh
  • Methods of treating diseases associated with high-fat diet and vitamin a deficiency using retinoic acid receptor agonists
    Patent number: 11207277
    Abstract: This invention relates to pharmaceutical composition and methods of using vitamin A and/or RAR? agonist for the treatment or prevention of diseases or conditions associated with high fat diet and/or vitamin deficiency.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 28, 2021
    Assignee: CORNELL UNIVERISITY
    Inventors: Lorraine J Gudas, Yannick Benoit, Ronald Perez, Xiao-Han Tang, Steven Trasino